Maintenance Herceptin duration- pro
A recent review looked at the question of maitnenance long term Hercerptin. The literature search found no specific evidence about the optimal duration of trastuzumab maintenance therapy in her2-positive mbc in prolonged remission. However, retrospective studies suggest predictive markers of good prognosis in patients in complete remission taking maintenance trastuzumab. Identifying those markers could lead to more personalized treatment. The survey of oncologists about their treatment practices in her2-positive mbc patients revealed that 82.93% of respondents (n = 34) follow the currently available guidelines.
R. Haq, MD and P. Gulasingam, MBB, Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission. Curr Oncol. 2016 Apr; 23(2): 9195.
NCCN, Breast Cancer 201